Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Feb 18;127(7):799-800.
doi: 10.1182/blood-2016-01-689042.

Might haplo "be the (better) match"?

Jennifer A Kanakry  1 , Leo Luznik  2
Affiliations
Comment

Might haplo "be the (better) match"?

Jennifer A Kanakry et al. Blood. .

Abstract

In this issue of Blood, in a registry study by Kanate et al of reduced-intensity conditioning allogeneic blood or marrow transplantation (BMT) outcomes for lymphoma, HLA-haploidentical (haplo) transplantation with posttransplantation cyclophosphamide (PTCy) is associated with similar rates of relapse and survival as HLA-matched unrelated donor (MUD) transplantation but lower rates of grades III to IV acute and chronic graft-versus-host disease (GVHD).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Comment on

  • Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
    Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M. Kanate AS, et al. Blood. 2016 Feb 18;127(7):938-47. doi: 10.1182/blood-2015-09-671834. Epub 2015 Dec 15. Blood. 2016. PMID: 26670632 Free PMC article. Clinical Trial.

References

    1. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016 127(7):938-947. - PMC - PubMed
    1. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91. - PubMed
    1. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24. - PMC - PubMed
    1. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310–1316. - PubMed
    1. Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573–1579. - PubMed